Eli Lilly stock dips as single-dose Zepbound price is cut in half
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Deutsche Bank on Eli Lilly (LLY): 'Zep Going (Lilly) Direct to Vials Helps Bridge GLP-1 Supply/Demand'
August 27, 2024 10:26 AM EDTDeutsche Bank analyst James Shin reiterated a Buy rating and $1,025.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "As noted on their 2Q24 call, LLY this AM formally stated Zepbound vials (2.5mg and 5.0mg) will be available via LillyDirect's self-pay channel. Monthly... More
